Cancer risk associated with anti-TIF1 antibodies

Press/Media: Expert comment

Release date: 7/1/2019

Description

Research highlight within Nature Reviews Rheumatology

Media contributions

TitleCancer risk associated with anti-TIF1 antibodies
Degree of recognitionInternational
Media name/outletNature Reviews Rheumatology
Media typePrint
CountryUnited Kingdom
Date7/01/19
Descriptionatients with dermatomyositis are more likely to develop cancer if they are positive for anti-transcriptional intermediary factor 1 (TIF1) antibodies than if they are negative (HR 3.4 (95% CI 2.2–5.4)), according to the results of a UK study of 263 patients. During a 10-year follow-up period, cancer occurred exclusively within a 3-year window either side of diagnosis in anti-TIF1 antibody-positive patients and was most common in patients over the age of 39. Patients with anti-TIF1 antibodies also had a higher risk of ovarian cancer than those without (19% of cancers versus 2% of cancers, respectively; P < 0.05).
Producer/AuthorJoanna Collison
URLhttps://www.nature.com/articles/s41584-019-0164-3
PersonsHector Chinoy, Alexander Oldroyd, Janine Lamb

Related information